Surgical Bleeding and Acquired Coagulopathy Reviews

1. Edmunds LH Jr. Hemostatic problems in surgical patients. In: Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber SZ, eds. Hemostasis & Thrombosis: Basic Principles and Clinical Practice. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2006:1103-1120.
2. Leung LL. Perioperative evaluation of bleeding diathesis. Hematology Am Soc Hematol Educ Program. 2006:457-461.
3. Dagi TF. The management of postoperative bleeding. Surg Clin North Am. 2005;85(6):1191-1213.
4. Franchini M, Veneri D. Acquired coagulation inhibitor-associated bleeding disorders: an update. Hematology. 2005;10(6):443-449.
5. Lollar P. Pathogenic antibodies to coagulation factors. Part II. Fibrinogen, prothrombin, thrombin, factor V, factor XI, factor XII, factor XIII, the protein C system and von Willebrand factor. J Thromb Haemost. 2005;3(7):1385-1391.
6. Lollar P. Pathogenic antibodies to coagulation factors. Part one: Factor VIII and factor IX. J Thromb Haemost. 2004;2(7);1082-1095.

Heparin-Induced Thrombocytopenia (HIT) Clinical Trials and Reviews

1. Crespo EM, Oliveira GB, Honeycutt EF, et al; CATCH Registry Investigators. Evaluation and management of thrombocytopenia and suspected heparin-induced thrombocytopenia in hospitalized patients: The Complications After Thrombocytopenia Caused by Heparin (CATCH) registry. Am Heart J. 2009;157(4):651-657.
2. Warkentin TE, Sheppard JA, Moore JC, Cook RJ, Kelton JG. Studies of the immune response in heparin-induced thrombocytopenia. Blood. 2009;113(20):4963-4969.
3. Wilke T, Tesch S, Scholz A, Kohlmann T, Greinacher A. The costs of heparin-induced thrombocytopenia: a patient-based cost of illness analysis. J Thromb Haemost. 2009;7(5):766-773.
4. Greinacher A, Kohlmann T, Strobel U, Sheppard JA, Warkentin TE. The temporal profile of the anti-PF4/heparin immune response. Blood. 2009;113(20):4970-4976.
5. Baroletti S, Piovella C, Fanikos J, Labreche M, Lin J, Goldhaber SZ. Heparin-induced thrombocytopenia (HIT): clinical and economic outcomes. Thromb Haemost. 2008;100(6):1130-1135.
6. Kelton J, Warkentin T. Heparin-induced thrombocytopenia: a historical perspective. Blood. 2008;112(7):2607-2616.
7. Warkentin TE, Greinacher A, Koster A, Lincoff AM; American College of Chest Physicians. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 suppl):340S-380S.
8. Arepally GM, Ortel TL. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med. 2006;355(8):809-817.
9. Warkentin TE. Pork or beef? Ann Thorac Surg. 2003;75(1):15-16.
10. Rice L, Attisha WK, Drexler A, Francis JL. Delayed-onset heparin-induced thrombocytopenia. Ann Intern Med. 2002;136(3):210-215.

Bovine Thrombin-Associated Immunogenicity Articles

1. Bomgaars L, Carberry K, Fraser C, West A, Teruya J. Development of factor V and thrombin inhibitors in children following bovine thrombin exposure during cardiac surgery: a report of three cases. Congenit Heart Dis. 2010;5(3):303-308.
2. Clark JA, Humphries JE, Crean S, Reynolds MW. Topical bovine thrombin: a 21-year review of topical bovine thrombin spontaneous case safety reports submitted to FDA’s Adverse Event Reporting System. Pharmacoepidemiol Drug Saf. 2010;19(2):107-114.
3. Foster KN, Kim H, Potter K, Matthews MR, Pressman M, Caruso DM. Acquired factor V deficiency associated with exposure to bovine thrombin in a burn patient. J Burn Care Res. 2010;31(2):353-360.
4. Rodgers GM, Kraiss LW. Severe postoperative immune-mediated coagulopathy associated with bovine thrombin exposure. Pharmacotherapy. 2010;30(8):319e-324e.
5. Kessler CM, Ortel TL. Recent developments in topical thrombins. Thromb Haemost. 2009;102(1):15-24.
6. Naoum JJ. Immune-mediated coagulopathy: a case report. Pharmacotherapy. 2009;29(7Pt2):13S-17S.
7. Ness P, Creer M, Rodgers GM, et al; the Recognition, Evaluation and Treatment of Acquired Coagulopathy Consensus (RETACC) Panel. Building an immune-mediated coagulopathy consensus: early recognition and evaluation to enhance post-surgical patient safety. Patient Saf Surg. 2009;3(1):8.
8. Clark J, Crean S, Reynolds MW. Topical bovine thrombin and adverse events: a review of the literature. Curr Med Res Opin. 2008;24(7):2071-2087.
9. Doria CM, Fischer CP, Wood CG, et al. Phase 3, randomized, double-blind study of plasma-derived human thrombin versus bovine thrombin in achieving hemostasis in patients undergoing cardiovascular, neurologic, and general surgery. Curr Med Res Opin. 2008;24(3):785-794.
10. Reynolds MW, Clark J, Crean S, Samudrala S. Risk of bleeding in surgical patients treated with topical bovine thrombin sealants: a review of the literature. Patient Saf Surg. 2008;2:5.
11. Chapman WC, Singla N, Genyk Y, et al. A phase 3, randomized, double-blind comparative study of the efficacy and safety of topical recombinant human thrombin and bovine thrombin in surgical hemostasis. J Am Coll Surg. 2007;205(2):256-265.
12. Crow SS, Sullivan VV, Aysola AE, et al. Postoperative coagulopathy in a pediatric patient after exposure to bovine topical thrombin. Ann Thorac Surg. 2007;83(4):1547-1549.
13. O'Connell K, Lindsey K, Wise R. Biologic fibrin sealant safety surveillance. Poster presented at: 23rd ICPE; August 19-22, 2007; Québec City, Québec.
14. Savage WJ, Kickler TS, Takemoto CM. Acquired coagulation factor inhibitors in children after topical bovine thrombin exposure. Pediatr Blood Cancer. 2007;49(7):1025-1029.
15. Kapoor A, Cortese Hassett AL, Bontempo FA. Lack of response bleeding from acquired factor V inhibitor to recombinant human factor VIIa concentrate [abstract 4099]. Blood. 2005;106(11). http://abstracts.hematologylibrary.org/cgi/content/abstract/106/11/4099. Accessed January 8, 2009.
16. Kirkeby KM, Aronowitz P. Acquired factor V inhibitor: a common and avoidable complication of topical bovine thrombin application. Am J Med. 2005;118(7):805.
17. Lawson JH, Lynn KA, Vanmatre RM, et al. Antihuman factor V antibodies after use of relatively pure bovine thrombin. Ann Thorac Surg. 2005;79(3):1037-1038.
18. Shah AK, Moreno-Aspitia A. Acquired factor V inhibitor and single exposure to autologous growth factor. Thromb Res. 2005;116(1):87-89.
19. Sarfati MR, Dilorenzo DJ, Kraiss LW, Galt SW. Severe coagulopathy following intraoperative use of topical thrombin. Ann Vasc Surg. 2004;18(3):349-351.
20. Poynton AR, Nelson MC, McCance SE, Levine RL, O'Leary PF. Bovine thrombin induces an acquired coagulopathy in sensitized patients undergoing revision spinal surgery: a report of two cases. Spine. 2003;28(12):E221-E223.
21. Boshkov LK, Thomas G, Reller M, Roberts C, Shen I. Bleeding due to acquired antibody to factor V followed by stroke associated with high titer anticardiolipin (ACLA) antibody in a 14 month old congenital cardiac patient exposed to topical bovine thrombin [Abstract 3902]. Blood. 2002;100(11).
22. Neschis DG, Heyman MR, Cheanvechai V, Benjamin ME, Flinn WR. Coagulopathy as a result of factor V inhibitor after exposure to bovine topical thrombin. J Vasc Surg. 2002;35(2):400-402.
23. Streiff MB, Ness PM. Acquired FV inhibitors: a needless iatrogenic complication of bovine thrombin exposure. Transfusion. 2002;42(1):18-26.
24. Su Z, Izumi T, Thames EH, Lawson JH, Ortel TL. Antiphospholipid antibodies after surgical exposure to topical bovine thrombin. J Lab Clin Med. 2002;139(6):
    349-356.
    
25. Weaver FA, Hood DB, Zatina M, Messina L, Badduke B. Gelatin-thrombin-based hemostatic sealant for intraoperative bleeding in vascular surgery. Ann Vasc Surg. 2002;16(3):286-293.
26. Winterbottom N, Kuo JM, Nguyen K, et al. Antigenic responses to bovine thrombin exposure during surgery: a prospective study of 309 patients. J Appl Res. 2002;2(1):1-11.
27. Adams JD, Jones S, Brost BC. Development of antibodies to topical bovine thrombin after abdominal hysterectomy. A case report. J Reprod Med. 2001;46(10):909-912.
28. Nelson PA, Powers JN, Estridge TD, et al. Serological analysis of patients treated with a new surgical hemostat containing bovine proteins and autologous plasma. J Biomed Mater Res. 2001;58(6):710-719.
29. Ortel TL, Mercer MC, Thames EH, Moore KD, Lawson JH. Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin. Ann Surg. 2001;233(1):88-96.
30. Pavlovich CP, Battiwalla M, Rick ME, Walther MM. Antibody induced coagulopathy from bovine thrombin use during partial nephrectomy. J Urol. 2001;165(5):1617.
31. Sands JJ, Nudo SA, Moore KD, Ortel TL. Antibodies to prothrombin, factor V, and beta2-glycoprotein I and vascular access thrombosis. ASAIO J. 2001;47(5):
    507-510.
    
32. Schleinitz N, Veit V, Chouquet D, et al. Acquired factor V inhibitor: etiology, bleeding risk and therapeutic management with regard to three cases. Rev Med Interne. 2001;22(11):1119-1123.